Are defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita rescued by a peptide from the dyskerin TruB domain?
These data indicate that supplying GSE24.2, either from a cDNA vector, or as a peptide, can reduces the pathogenic effects of Dkc1 mutations and could form the basis of a novel therapeutic approach.
Preoperative thrombocytosis was valuable for predicting the prognosis of patients with NSCLC. Special attention should be paid to patients with preoperative and postoperative thrombocytosis.